Modern strategies of regenerative therapy and safety of allogenous human umbilical cord blood stem cellsadministration for neurodegenerative diseases
- Authors: Smolyaninov AB1, Hurtsilava OG2, Tyrenko VV3, Novitsky AV3, Ivolgin DA4
-
Affiliations:
- Saint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-PetersburgPokrovsky Stem Cells Bank, Saint-Petersburg
- Saint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-Petersburg
- S.M. Kirov Military Medical Academy of the RF Ministry of Defense, Saint-Petersburg
- Pokrovsky Stem Cells Bank, Saint-Petersburg
- Issue: Vol 6, No 4 (2011)
- Pages: 14-20
- Section: Articles
- Submitted: 11.01.2023
- Published: 15.12.2011
- URL: https://genescells.ru/2313-1829/article/view/121662
- DOI: https://doi.org/10.23868/gc121662
- ID: 121662
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Biotechnological market in harvesting and application of
umbilical cord blood stem cells, is permanently developing in
the world. Efficiency of regenerative therapy, based on use
of cord blood stem cells depends on the number and diversity
of HLA-typed cord blood units. Human umbilical cord blood is
a genuine source of the stem cells rich biological material,
important for human. 114 patients with neurodegenerative
diseases were transplanted with allogenic umbilical cord
blood. Cord blood stem cells were used without selection by
HLA antigens, but only by ABO blood group and Rh factor. The
possibility of using of allogenic umbilical cord blood stem cells
in regenerative therapy, and the lack of immunosupression
will overcome significant obstacles existing in cell therapy to
date. In practical terms, its becoming clear that extensive
application of allogenic umbilical cord blood stem cells
regenerative therapy will seriously changes approaches to the
development and delivery of umbilical blood stem cells-based
drugs existing nowadays and approved by many generations
of doctors.
umbilical cord blood stem cells, is permanently developing in
the world. Efficiency of regenerative therapy, based on use
of cord blood stem cells depends on the number and diversity
of HLA-typed cord blood units. Human umbilical cord blood is
a genuine source of the stem cells rich biological material,
important for human. 114 patients with neurodegenerative
diseases were transplanted with allogenic umbilical cord
blood. Cord blood stem cells were used without selection by
HLA antigens, but only by ABO blood group and Rh factor. The
possibility of using of allogenic umbilical cord blood stem cells
in regenerative therapy, and the lack of immunosupression
will overcome significant obstacles existing in cell therapy to
date. In practical terms, its becoming clear that extensive
application of allogenic umbilical cord blood stem cells
regenerative therapy will seriously changes approaches to the
development and delivery of umbilical blood stem cells-based
drugs existing nowadays and approved by many generations
of doctors.
About the authors
A B Smolyaninov
Saint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-PetersburgPokrovsky Stem Cells Bank, Saint-PetersburgSaint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-PetersburgPokrovsky Stem Cells Bank, Saint-Petersburg
O G Hurtsilava
Saint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-PetersburgSaint-Petersburg Medical Academy of Postgraduate Studies of Roszdrav, Saint-Petersburg
V V Tyrenko
S.M. Kirov Military Medical Academy of the RF Ministry of Defense, Saint-PetersburgS.M. Kirov Military Medical Academy of the RF Ministry of Defense, Saint-Petersburg
A V Novitsky
S.M. Kirov Military Medical Academy of the RF Ministry of Defense, Saint-PetersburgS.M. Kirov Military Medical Academy of the RF Ministry of Defense, Saint-Petersburg
D A Ivolgin
Pokrovsky Stem Cells Bank, Saint-PetersburgPokrovsky Stem Cells Bank, Saint-Petersburg
References
- Hutton J.F., Gargett T., Sadlon T.J. et al. Development of CD4+CD25+FoxP3+ regulatory T-cells from cord blood hematopoietic progenitor cells. Leukoc. Biol. 2009; 85: 445-1.
- Haller M.J., Wasserfall C.H., McGrail K.M. et al. Autologous umbilical cord blood transfusion in very young children with type I diabetes. Diabetes Care. 2009; 32: 2041-.
- Moon Y.J., Yoon H.H., Lee M.W. et al. Multipotent progenitor cells derived from human umbilical cord blood can differentiate into hepatocyte-like cells in a liver injury rat model. Transplant. Proc. 2009; 41: 4357-0.
- Riordan N.H., Ichim T.E., Min W.P. et al. Nonexpanded adipose stromal vascular fraction cell therapy for multiple sclerosis. Transl. Med. 2009; 7: 29.
- Javed M.J., Mead L.E., Prater D. et al. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatr. Res. 2008; 64: 68-3.
- Gratwohl A., Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr. Opin. Hematol. 2009; 16: 420-.
- Harris D.T. Non-haematological uses of cord blood stem cells. Br. J. Haematol. 2009; 147: 177-4.
- Liu W.S., Chen C.T., Foo N.H. et al. Human umbilical cord blood cells protect against hypothalamic apoptosis and systemic inflammation response during heatstroke in rats. Pediatr. Neonatol. 2009; 50: 208-6.
- Xiao J., Nan Z., Motooka Y. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. Stem Cells Dev. 2005;14: 722-3.
- Riordan N.H., Chan K., Marleau A.M. Cord blood in regenerative medicine: do we need immune suppression? Transl. Med. 2007; 5: 8.
- Ghen M.J., Roshan R., Roshan R.O. et al. Potential clinical applications using stem cells derived from human umbilical cord blood. Reprod. Biomed. Online. 2006; 13: 562-2.
- Xing Y.L., Shen L.H., Li H.W. et al. Optimal time for human umbilical cord blood cell transplantation in rats with myocardial infarction. Chin. Med. J. (Engl). 2009; 122: 2833-39.
- Ichim T.E., Solano F., Brenes R. et al. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod. Biomed. Online. 2008; 16: 898-905.
- Yang W.Z., Zhang Y., Wu F. et al. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions (Shenzhen Beike Cell Engineering Research Institute, Shenzhen, China). Transl. Med. 2010; 8(75): 1-6.
- Hwang W.S., Chen S.H., Lin C.H. et al. Human umbilical cord blood-derived CD34+ cells can be used as a prophylactic agent for experimental heatstroke. J. Pharmacol. Sci. 2008; 106: 46-55.
- Garbuzova-Davis S., Willing A.E., Zigova T. et al. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. Hematother. Stem Cell Res. 2003; 12: 255-70.
- Bachstetter A.D., Pabon M.M., Cole M.J. et al. Perepheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain. BMC Neurosci. 2008; 9: 22.
Supplementary files
